Momenta Pharmaceuticals, Inc. (MNTA) Director Elizabeth Stoner Sells 5,500 Shares of Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Elizabeth Stoner sold 5,500 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $13.10, for a total value of $72,050.00. Following the completion of the transaction, the director now directly owns 13,240 shares of the company’s stock, valued at $173,444. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded up $0.55 during midday trading on Friday, reaching $13.60. The company’s stock had a trading volume of 1,983,286 shares, compared to its average volume of 598,954. Momenta Pharmaceuticals, Inc. has a 52-week low of $11.85 and a 52-week high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. The firm had revenue of $24.09 million during the quarter, compared to analyst estimates of $29.58 million. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The firm’s quarterly revenue was down 17.3% on a year-over-year basis. During the same period last year, the company posted ($0.26) EPS. equities research analysts predict that Momenta Pharmaceuticals, Inc. will post -1.16 earnings per share for the current year.

A number of equities analysts recently issued reports on MNTA shares. Goldman Sachs Group started coverage on Momenta Pharmaceuticals in a report on Thursday, September 28th. They issued a “neutral” rating and a $18.00 price objective for the company. Zacks Investment Research lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Robert W. Baird lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $22.00 to $15.00 in a report on Friday, October 6th. Cowen set a $15.00 price objective on Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 1st. Finally, BidaskClub lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Three investment analysts have rated the stock with a sell rating and nine have issued a hold rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $15.00.

A number of hedge funds and other institutional investors have recently modified their holdings of MNTA. Morgan Stanley boosted its stake in Momenta Pharmaceuticals by 11.4% during the 1st quarter. Morgan Stanley now owns 273,724 shares of the biotechnology company’s stock valued at $3,655,000 after purchasing an additional 28,069 shares in the last quarter. Aperio Group LLC boosted its stake in Momenta Pharmaceuticals by 9.4% during the 2nd quarter. Aperio Group LLC now owns 18,151 shares of the biotechnology company’s stock valued at $307,000 after purchasing an additional 1,562 shares in the last quarter. Strs Ohio boosted its stake in Momenta Pharmaceuticals by 218.7% during the 2nd quarter. Strs Ohio now owns 52,900 shares of the biotechnology company’s stock valued at $894,000 after purchasing an additional 36,300 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in Momenta Pharmaceuticals by 8.1% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 15,780 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 1,180 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its stake in Momenta Pharmaceuticals by 8.4% during the 2nd quarter. Great West Life Assurance Co. Can now owns 96,471 shares of the biotechnology company’s stock valued at $1,625,000 after purchasing an additional 7,450 shares in the last quarter. 93.45% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) Director Elizabeth Stoner Sells 5,500 Shares of Stock” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://stocknewstimes.com/2017/12/16/momenta-pharmaceuticals-inc-mnta-director-elizabeth-stoner-sells-5500-shares-of-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply